Demcizumab

Drug Profile

Demcizumab

Alternative Names: Anti-delta-like ligand 4 monoclonal antibody; Anti-DLL4 monoclonal antibody; OMP-18M21; OMP-21M18

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer Celgene Corporation; OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 01 Dec 2016 OncoMed completes a phase Ib trial in Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia, New Zealand and Spain (IV) (NCT01189929)
  • 01 Sep 2016 OncoMed Pharmaceuticals completes a phase Ib trial for Non-small cell lung cancer (combination therapy, first-line therapy, late-stage disease, metastatic disease, recurrent, inoperable/ unresectable) in Australia, New Zealand and Spain (NCT01189968)
  • 01 Sep 2016 OncoMed Pharmaceuticals completes enrolment in the phase II trial for Pancreatic cancer in Australia, Belgium, Canada, Spain, United states and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top